h460 cells (Procell Inc)
Structured Review

H460 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/h460+cells/pmc13194821-296-10-12?v=Procell+Inc
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Ceramide disrupts TM9SF2-PGK1 axis to redirect PD-L1 trafficking and enhance antitumor immunity"
Article Title: Ceramide disrupts TM9SF2-PGK1 axis to redirect PD-L1 trafficking and enhance antitumor immunity
Journal: Nature Communications
doi: 10.1038/s41467-026-70764-x
Figure Legend Snippet: A An outline of the CRISPR-Cas9-based deletion library screen targeting genes related to sphingolipid synthesis or transport essential for cell surface PD-L1 expression. H460 cells expressing Cas9 were mutagenized with a focused lentiviral sgRNA library and PD-L1 low cells enriched by FACS sorting. B Significant hits identified from cellular screens are shown. LFC: The log2 fold change of sgRNA. C PD-L1 expression in sgNTC and sg TM9SF1-4 H460 cells was analyzed by Western blot. NTC: No Template Control. D Western blot assessment to evaluate PD-L1 expression in H460 cells overexpressing FLAG-tagged TM9SF1-4 versus empty vector (EV). FLAG antibody is used for the detection of TM9SF1/3/4. TM9SF2 antibody is used for the detection of TM9SF2. E The lifetime of PD-L1 was assessed in sgNTC and sg TM9SF1-4 H460 cells administered cycloheximide (CHX, 25 µg/mL) over time. PD-L1 levels were standardized to GAPDH. F A schematic overview of the T-cell-reliant cytotoxicity is shown. H460 cells transduced using TM9SF2 -targeting sgRNA or control sgRNA were co-cultured with activated T cells. Cytotoxicity was evaluated through clonogenic assays, survival analyses, and apoptosis measurements. G Cell viability showing T-cell cytotoxicity in H460 cells with TM9SF2 depletion following activated T cells co-culture. H , I Quantitative analysis of IFN-γ and CD107a expression in CD8 + T cells derived from co-culture are shown ( n = 5 independent experiments). Data are presented as mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Source data are provided as a file.
Techniques Used: CRISPR, Expressing, Western Blot, Control, Plasmid Preparation, Cell Culture, Co-Culture Assay, Derivative Assay
Figure Legend Snippet: A Top five identified positive regulators ranked by enrichment scores from the immunoprecipitation-mass spectrometry (IP-MS) screen. Immunoprecipitation was performed using anti-FLAG beads in HEK293T cells transfected using TM9SF2 -FLAG. For B – E , G , HA antibody is used for the detection of HA-tagged PGK1. B Co-immunoprecipitation assays validating the interactions between TM9SF2 and PGK1 in H460 cells after 48 h of IFN-γ stimulation (100 ng/mL). C Western blot analysis of PGK1 and PD-L1 in H460 cells transduced with PGK1 sgRNAs versus sgNTC or H460 cells overexpressing HA-tagged PGK1 ( n = 3 independent experiments). D Co-immunoprecipitation assays demonstrating the association between TM9SF2 and PGK1 wild-type, S203D (phosphorylation-mimetic mutant), or S203A (phosphorylation-deficient mutant). E Western blot analysis of PD-L1 levels in PGK1 -depleted H460 cells transfected with PGK1 wild type or phospho-mutants. F , G The half-life of PD-L1 was assessed in H460 cells with PGK1 depletion or overexpression following treatment with CHX (25 µg/mL). For H – J , C57BL/6 J mice underwent subcutaneous injection with B16 cells transduced with Pgk1 shRNA or control shRNA. H Representative images and volumes of B16 tumors. I Proportions of tumor-permeating CD8 + T cells in tumors ( n = 5 mice). J Flow cytometry analysis of IFN-γ and CD107a levels in tumor-permeating CD8 + T cells in tumors ( n = 5 mice). K Schematic of the experimental design: For L-N, C57BL/6 J mice were subcutaneously inoculated with B16 cells followed by daily intraperitoneal administration of DC-PGKI (a PGK1 inhibitor, 5 and 10 mg/kg) for one week. L Representative image of B16 tumors. M Proportions of tumor-permeating CD8 + T cells in tumors ( n = 5 mice). N The proportions of IFN-γ + and CD107a + tumor-permeating CD8 + T cells in tumors ( n = 5 mice). For O – Q , C57BL/6 J mice were injected with B16 cells overexpressing Pgk1 or EV. O Representative image of B16 tumors. P Proportions of tumor-permeating CD8 + T cells in tumors ( n = 5 mice). Q Flow cytometry analysis of IFN-γ and CD107a levels in tumor-permeating CD8 + T cells in tumors ( n = 5 mice). Data are presented as mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Source data are provided as a file.
Techniques Used: Immunoprecipitation, Mass Spectrometry, Protein-Protein interactions, Transfection, Western Blot, Transduction, Phospho-proteomics, Mutagenesis, Over Expression, Injection, shRNA, Control, Flow Cytometry
Figure Legend Snippet: A Bar plot showing altered cellular processes and signaling pathways in shTM9SF2 H460 cells compared to shNC cells. B A schematic of the PD-L1 surface internalization assay in H460 cells transduced with sgRNAs is shown. C Surface PD-L1 retention in H460 cells was measured by flow cytometry after genetic depletion of PGK1 or TM9SF2 ( n = 3 independent experiments). D PD-L1 recycling was quantified by flow cytometry in H460 cells following PGK1 or TM9SF2 knockout ( n = 3 independent experiments). E Immunofluorescence showing PD-L1 colocalization with RAB11 in sg PGK1 or sg TM9SF2 H460 cells versus sgNTC (PD-L1 in green, RAB11 in red, DAPI in blue). Scale bar: 5 μm. The right panels display intensity profiles of PD-L1 versus RAB11 following the white line. For F , G , HA antibody is used for the detection of HA-tagged PGK1. F Co-immunoprecipitation assay demonstrating TM9SF2 interaction with PGK1, RAB11, and PD-L1 in H460 cells, with or without IFN-γ treatment (100 ng/mL, 48 h). G Co-immunoprecipitation assay evaluating interactions of PGK1 wild-type and its phospho-mutants (S203A and S203D) using TM9SF2, PD-L1, and RAB11 in H460 cells. Data are presented as mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Source data are provided as a file.
Techniques Used: Protein-Protein interactions, Transduction, Flow Cytometry, Knock-Out, Immunofluorescence, Co-Immunoprecipitation Assay
Figure Legend Snippet: A Heatmap showing increased proteins involved in PD-L1 lysosomal degradation in sgPGK1 H460 cells versus sgNTC cells. Western blot of HIP1R levels in sg PGK1 ( B ) and sg TM9SF2 ( C ) H460 cells versus sgNTC cells ( n = 3 independent experiments). For D – F , HA antibody is used for the detection of HA-tagged PGK1. D Half-life analysis of HIP1R abundance in CHX (25 μg/mL)-treated H460 cells with PGK1 depletion or HA- PGK1 overexpression. E Western blot analyses of HIP1R ubiquitination in H460 cells reconstituted with MYC- HIP1R and HA- PGK1 for 36 h, followed by treatment with MG132 (10 μM, 8 h) and with or without IFN-γ administration (100 ng/mL, 8 h). MYC antibody is used for the detection of MYC-tagged HIP1R. F Western blot analyses of HIP1R ubiquitination in HEK293T cells reconstituted using MYC- HIP1R and HA- PGK1 wild-type and phospho-mutants for 36 h, followed by MG132 treatment (10 μM, 8 h). G Co-immunoprecipitation analysis examining IFN-γ effects on PGK1 association with GFP-HIP1R Δ966-979 and GFP-HIP1R. H460 cells transfected with FLAG- PGK1 and either GFP- HIP1R or GFP- HIP1R Δ966-979 were treated with IFN-γ (100 ng/mL, 8 h). Flag antibody is used for the detection of FLAG-tagged PGK1 and GFP antibody is used for the detection of GFP-tagged HIP1R. H A schematic of GFP fusion constructs is shown, including HIP1R lysosomal sorting signal (LL/LI, GFP-S1) and its corresponding mutant (AA, GFP-S2). I CHX-chase assay showing GFP-S1 and GFP-S2 protein levels over time in sg PGK1 or sgNTC H460 cells treated with CHX (25 μg/mL). Source data are provided as a file.
Techniques Used: Western Blot, Over Expression, Ubiquitin Proteomics, Immunoprecipitation, Transfection, Construct, Mutagenesis
Figure Legend Snippet: A Summary of ceramides that were up- or down-regulated following TM9SF2 depletion in H460 cells from lipidomics analysis. B PD-L1 levels were analyzed using Western blot in H460 cells administered cholesteryl:phosphatidylcholine (CholPC) alone or CholPC loaded with ceramides and derivatives (31.25 μM, 40 h). C PD-L1 surface levels in H460 cells given cholPC alone or cholPC loaded with ceramides and derivatives (31.25 μM, 40 h) ( n = 3 independent experiments). D , E Half-life analysis of PD-L1 or HIP1R concentrations in H460 cells overexpressing TM9SF2 for the indicated time points following CHX (25 µg/mL) treatment. Cells underwent pre-treated using 31.25 μM cholPC loaded with Cer(d18:1/26:0) for 40 h. F Co-immunoprecipitation analysis investigating the effect of Cer(d18:1/26:0) on the interaction between PGK1 and TM9SF2. HEK293T cells pre-transfected with HA- PGK1 or FLAG- TM9SF2 were treated with or without Cer(d18:1/26:0) (31.25 μM, 40 h). HA antibody is used for the detection of HA-tagged PGK1. G Immunofluorescence showing colocalization of PD-L1 with RAB11 in H460 cells with or without Cer(d18:1/26:0) treatment (31.25 μM, 40 h). (PD-L1 in green, RAB11 in red, DAPI in blue.) Scale bars: 4 μm. Intensity of PD-L1 and RAB11 following the white line are shown in right panels. H Schematic of the experimental protocol: For I – K , C57BL/6 J mice were subcutaneously inoculated with B16 cells and then administered intraperitoneal injections of either CholPC or Cer(d18:1/26:0) (10 and 20 mg/kg/day) for one week. All statistical comparisons were performed against the CholPC-treated control group. I Representative image of B16 tumors. J Proportion of tumor-permeating CD8 + T cells in B16 tumors ( n = 5 mice). K IFN-γ and CD107a levels in tumor-permeating CD8 + T cells in B16 tumors ( n = 5 mice). Data are presented as mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Source data are provided as a file.
Techniques Used: Western Blot, Immunoprecipitation, Transfection, Immunofluorescence, Control

